Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets extend rally
Fri, 3 Jul 11:30 am

After opening the day in the green the Indian stock market indices have made further gains. Buying interest is highest in the capital goods sector.

The BSE-Sensex is trading up by 145 points (0.52%) and the NSE-Nifty is trading up by 18 points (0.20%). The BSE Mid Cap index is trading up by 20 points (0.18%), while the BSE Small Cap index is trading up by 58 points (0.50%). The rupee is trading at 63.38 to the US dollar. Gold and Silver are trading at Rs 26,226 per 10 grams & Rs 35,891 per kilogram respectively.

Stocks in the Automobile sector are trading on a mixed note with Bajaj Auto trading up by 0.8% and Ashok Leyland trading down by 1.5%. Tata Motors entered the auto-rickshaw space in Ahmedabad with its four-wheeler CNG vehicle called 'Magic Iris'. It offers a fuel efficiency of 29.6 km per litre and is equipped with a 611 cc single cylinder engine. It has been priced at around Rs 3.41 lakh which is much higher than the conventional rickshaws which are priced at around Rs 2 lakh. Tata Motors claims that the Magic Iris would allow the rickshaw driver to make more trips and drive up to 100-120 kms per day without physical fatigue. The company is working on making easy finance options available to its buyers so that initial higher price does not hurt the buyer. They have tied up with several public sector banks for this purpose. Tata Motors is trading down by 1%.

Stocks in the Indian Pharma sector are trading on a positive note with Wockhardt and Elder Pharma leading the winners. Lupin has acquired a 100% stake for an undisclosed amount in a Russian company named 'Biocom'. Biocom is a generic drug maker with focus on therapies for cardiovascular diseases, central nervous system and antimicrobials for systematic use. It also does contract manufacturing and secondary packaging. This is the second overseas acquisition which Lupin made this year. It had acquired a 100% stake in Brazil's 'Medquimica' earlier in May. Biocom recorded sales of Rs 982 m in financial year 2014. Lupin is trading up by 1.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets extend rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.